From: Patient access schemes in Asia-pacific markets: current experience and future potential
Technology | Indication | Company | Payer | Type | Source |
---|---|---|---|---|---|
Cancer (n = 29) | |||||
Dasatinib | CML | Bristol-Myers Squibb Australia Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Nilotinib | CML | Novartis Pharmaceuticals Australia Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Imatinib | GIST, adjuvant | Novartis Pharmaceuticals Australia Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Imatinib | GIST, metastatic | Novartis Pharmaceuticals Australia Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Lapatinib | Late stage metastatic breast cancer | GlaxoSmithKline Australia Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Imatinib | Rare cancers (eg dermatofibrosarcoma protuberans, chronic eosinophilic leukemia) | Novartis Pharmaceuticals Australia Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Pazopanib | RCC | GlaxoSmithKline Australia Pty Ltd | PBS | Financially-based; Outcome-based | Public Summary Document [18] |
Bevacizumab | Metastatic colorectal cancerr | Roche Products Pty Ltd | PBS | Financially-based; Outcome-based | Public Summary Document [18] |
Sorafenib | Advanced hepatocellular carcinoma | Bayer Australia Ltd | PBS | Financially-based; Outcome-based | Public Summary Document [18] |
PET | Staging of newly diagnosed NSCLC, esophageal cancer, cancer of gastro-esophageal junction, head and neck cancer, suspected residual/metastatic/recurrent colorectal cancer, melanoma, head and neck cancer, ovarian cancer | Not specified | MBS | Evidence generation | Stafinski et al. 2010 [15] |
Exemestane | Oestrogen-receptor positive advanced breast cancer in post-menopausal women | Pfizer Australia Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Imiquimod | Superficial basal cell carcinoma | 3Â M Pharmaceuticals Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Letrozole | Advanced breast cancer in postmenopausal women | Novartis Pharmaceuticals Australia Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Docetaxel | SCCHN | Sanofi-Aventis Australia Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Sunitinib | RCC | Pfizer Australia Pty Ltd | PBS | Financially-based | |
Cetuximab | K-RAS wild mCRC | Merck Serono Australia Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Vemurafenib | Untreated unresectable stage IIIC or stage IV melanoma | Roche Products Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Imatinib | ALL | Novartis Pharmaceuticals Australia Pty Ltd | PBS | Financially-based; Outcome-based | PBPA Relativity Sheets [17], Public Summary Document [18], Medicare Australia [14] |
Dasatinib | ALL | Bristol-Myers Squibb Australia Pty Ltd | PBS | Financially-based; Outcome-based | PBPA Relativity Sheets [17], Public Summary Document [18], Medicare Australia [14] |
Azacitidine | CML | Celgene Pty Ltd | PBS | Financially-based; Outcome-based | |
Azacitidine | AML | Celgene Pty Ltd | PBS | Financially-based; Outcome-based | |
Azacitidine | Myelodysplastic syndrome | Celgene Pty Ltd | PBS | Financially-based; Outcome-based | |
Imatinib | CML | Novartis Pharmaceuticals Australia Pty Ltd | PBS | Financially-based; Outcome-based | |
Trastuzumab | HER2+ early breast cancer | Roche Products Pty Ltd | PBS | Financially-based; Outcome-based | |
Sunitinib | GIST | Pfizer Australia Pty Ltd | PBS | Financially-based; Outcome-based | |
Lenalidomide | Myelodysplastic syndrome | Celgene Pty Ltd | PBS | Financially-based; Outcome-based | |
Lenalidomide | Multiple myeloma | Celgene Pty Ltd | PBS | Financially-based; Outcome-based | |
Bortezomib | Multiple myeloma | Janssen-Cilag Pty Ltd | PBS | Financially-based, Outcome-based | PBS Schedule [16], PBPA Relativity Sheets [17], Public Summary Document [18], Medicare Australia [14] |
Erlotinib | Non-small cell lung cancer | Roche Products Pty Ltd | PBS | Financially-based; Outcome-based | |
Inflammatory Conditions (n = 28) | |||||
Adalimumab | Ankylosing spondylitis | AbbVie Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Etanercept | Ankylosing spondylitis | Pfizer Australia Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Golimumab | Ankylosing spondylitis | Janssen-Cilag Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Infliximab | Ankylosing spondylitis | Janssen-Cilag Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Adalimumab | Crohn’s disease | AbbVie Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Infliximab | Complex refractory fistulising Crohn’s disease | Janssen-Cilag Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Adalimumab | Juvenile arthritis | AbbVie Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Etanercept | Juvenile arthritis | Pfizer Australia Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Adalimumab | Psoriatic arthritis | AbbVie Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Golimumab | Psoriatic arthritis | Janssen-Cilag Pty Ltd( | PBS | Outcome-based | Medicare Australia [14] |
Infliximab | Psoriatic arthritis | Janssen-Cilag Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Pimecrolimus | Atopic dermatitis who are over 18Â years of age | Novartis Pharmaceuticals Australia | PBS | Financially-based | Public Summary Document [18] |
Infliximab | Crohn’s disease | Janssen-Cilag Pty Ltd | PBS | Financially-based; Outcome-based | |
Adalimumab | Complex refractory fistulising Crohn’s disease | AbbVie Pty Ltd | PBS | Financially-based; Outcome-based | |
Tocilizumab | Juvenile arthritis | Roche Products Pty Ltd | PBS | Financially-based; Outcome-based | |
Abatacept | RA | Novartis Pharmaceuticals Australia Pty Ltd | PBS | Financially-based; Outcome-based | |
Infliximab | RA | Janssen-Cilag Pty Ltd | PBS | Financially-based; Outcome-based | PBS Schedule [16], Lu et al. 2007 [33], Pugatch et al. 2010 [21], Medicare Australia [14] |
Rituximab | RA | Roche Products Pty Ltd | PBS | Financially-based; Outcome-based | PBS Schedule [16], Lu et al. 2007 [33], Pugatch et al. 2010 [21], Medicare Australia [14] |
Tocilizumab | RA | Roche Products Pty Ltd | PBS | Financially-based; Outcome-based | |
Certolizumab Pegol | RA | UCB Australia Proprietary Ltd | PBS | Financially-based; Outcome-based | |
Adalimumab | RA | AbbVie Pty Ltd | PBS | Financially-based; Outcome-based | PBS Schedule [16], Lu et al. 2007 [33], Pugatch et al. 2010 [21], Medicare Australia [14] |
Golimumab | RA | Janssen-Cilag Pty Ltd | PBS | Financially-based; Outcome-based | |
Etanercept | RA | Pfizer Australia Pty Ltd | PBS | Financially-based; Outcome-based | PBS Schedule [16], Lu et al. 2007 [33], Pugatch et al. 2010 [21], Medicare Australia [14] |
Adalimumab | Severe chronic plaque psoriasis | AbbVie Pty Ltd | PBS | Financially-based; Outcome-based | PBS Schedule [16], Lu et al. 2007 [33], Pugatch et al. 2010 [21], Medicare Australia [14] |
Etanercept | Severe chronic plaque psoriasis | Pfizer Australia Pty Ltd | PBS | Financially-based; Outcome-based | |
Infliximab | Severe chronic plaque psoriasis | Janssen-Cilag Pty Ltd | PBS | Financially-based; Outcome-based | |
Ustekinumab | Severe chronic plaque psoriasis | Janssen-Cilag Pty Ltd | PBS | Financially-based; Outcome-based | |
Etanercept | Severe chronic plaque psoriasis under 18 | Pfizer Australia Pty Ltd | PBS | Financially-based; Outcome-based | |
Infectious Diseases (n = 7) | |||||
Abacavir | HIV infection | ViiV Healthcare Pty Ltd | PBS | Financially-based | |
Tipranavir | HIV infection | Boehringer Ingelheim Pty Ltd | PBS | Financially-based | |
Entecavir | Chronic hepatitis B in adults 16Â years and older with evidence of active liver inflammation | Bristol-Myers Squibb Australia Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Boceprevir | Chronic genotype 1 hepatitis C infection | Merck Sharp & Dohme (Australia) Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Telaprevir | Chronic genotype 1 hepatitis C | Janssen-Cilag Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Posaconazole | Invasive fungal infections, not responsive to or intolerant of, alternative therapy | Schering-Plough Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Posaconazole | Prophylaxis of invasive fungal infections among high risk patients | Schering-Plough Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Pulmonary Hypertension (n = 7) | |||||
Sildenafil | PPH or PAH | Pfizer Australia Pty Ltd | PBS | Outcome-based | |
Tadalafil | PPH or PAH | Eli Lilly Australia Pty Ltd | PBS | Outcome-based | |
Treprostinil Sodium | PPH or PAH | Orphan Australia Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Ambrisentan | PPH or PAH | GlaxoSmithKline Australia Pty Ltd | PBS | Financially-based; Outcome-based | |
Bosentan | PPH or PAH | Actelion Pharmaceuticals Australia Pty Ltd | PBS | Financially-based; Outcome-based | PBS Schedule [16], PBPA Relativity Sheets [17], Public Summary Document [18], Medicare Australia [14] |
Epoprostenol | PPH or PAH | GlaxoSmithKline Australia Pty Ltd | PBS | Financially-based; Outcome-based | PBS Schedule [16], PBPA Relativity Sheets [17], Public Summary Document [18], Medicare Australia [14] |
Iloprost trometamol | PPH or PAH | Bayer Australia Ltd | PBS | Financially-based; Outcome-based | |
Other (n = 27) | |||||
Modafinil | Narcolepsy | bioCSL (Australia) Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Verteporfin | Age-related macular degeneration | Novartis Pharmaceuticals Australia Pty Ltd | PBS | Outcome-based | Medicare Australia [14] |
Deep brain stimulation | Patients with Parkinson's disease no longer responsive to drug therapy | Not specified | MBS | Evidence generation | Stafinski et al. 2010 [15] |
EVAR | Abdominal aortic aneurysm | Not specified | MBS | Evidence generation | Stafinski et al. 2010 [15] |
Dabigatran | Prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation | Boehringer Ingelheim Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Atomoxetine Hydrochloride | ADHD diagnosed between the ages of 6 and 18Â years | Eli Lilly Australia Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Fingolimod | RRMS | Novartis Pharmaceuticals Australia Pty Ltd | PBS | Financially-based; Outcome-based | Public Summary Document [18] |
Cinacalcet Hydrochloride | End stage renal disease receiving dialysis who have uncontrolled secondary hyperparathyroidism | Amgen Australia Pty Ltd | PBS | Financially-based | |
Clostridium botulinum type A toxin-haemagglutinin complex | Severe spasticity of the upper limb in adults following a stroke, as an adjunct to physical therapy | Ipsen Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Fentanyl citrate | Fentanyl lozenges for the treatment of breakthrough pain | Orphan Australia Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Natalizumab | RRMS | Biogen Idec Australia Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Paliperidone | Schizophrenia | Janssen-Cilag Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Botulinum toxin type a purified neurotoxin complex | Moderate to severe spasticity of the upper limb in adults following a stroke as an adjunct to physical therapy | Allergan Australia Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Tenofovir Disoproxil Fumarate | Treatment of chronic hepatitis B | Gilead Sciences Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Pramipexole hydrochloride | Idiopathic Parkinson disease | Boehringer Ingelheim Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Tobramycin | Pseudomonas aeruginosa respiratory infection in a patient with Cystic Fibrosis | Novartis Pharmaceuticals Australia Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Ticagrelor | ACS, MI, or unstable angina | AstraZeneca Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Pregabalin | Neuropathic pain | Pfizer Australia Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Rivaroxaban | Acute symptomatic DVT | Bayer Australia Ltd | PBS | Financially-based | Public Summary Document [18] |
Aztreonam | Pseudomonas aeruginosa infection in patients with cystic fibrosis | Gilead Sciences Pty Ltd | PBS | Financially-based | Public Summary Document [18] |
Crinone (progesterone gel) | Supplement progesterone in women who have luteal phase defect | Merck Serono | PBS | Financially-based | |
Deferasirox (Exjade) | Chronic iron overload in patients with disorders of erythropoiesis | Novartis | PBS | Financially-based | |
Omalizumab | Uncontrolled severe allergic asthma | Novartis Pharmaceuticals Australia Pty Ltd | PBS | Financially-based; Outcome-based | |
Aflibercept | Age-related macular degeneration | Bayer Australia Ltd | PBS | Financially-based; Outcome-based | |
Ranibizumab | Age-related macular degeneration | Novartis Pharmaceuticals Australia Pty Ltd | PBS | Financially-based; Outcome-based | PBS Schedule [16], PBPA Relativity Sheets [17], Public Summary Document [18], Medicare Australia [14] |
Eltrombopag | Severe chronic immune idiopathic thrombocytopenic purpura | GlaxoSmithKline Australia Pty Ltd | PBS | Financially-based; Outcome-based | |
Romiplostim | Severe chronic immune idiopathic thrombocytopenic purpura | Amgen Australia Pty Ltd | PBS | Financially-based; Outcome-based |